Extracellular nucleotides affect pericyte-mediated regulation of rat in situ vasa recta diameter

被引:40
作者
Crawford, C. [1 ]
Kennedy-Lydon, T. M. [1 ]
Callaghan, H. [1 ]
Sprott, C. [1 ]
Simmons, R. L. [1 ]
Sawbridge, L. [1 ]
Syme, H. M. [2 ]
Unwin, R. J. [3 ]
Wildman, S. S. P. [1 ]
Peppiatt-Wildman, C. M. [1 ]
机构
[1] Univ London Royal Vet Coll, Urinary Syst Physiol Unit, Dept Vet Basic Sci, London NW1 0TU, England
[2] Univ London Royal Vet Coll, Dept Vet Clin Sci, London NW1 0TU, England
[3] UCL, Ctr Nephrol, Royal Free Hosp, Sch Med, London, England
基金
英国惠康基金; 英国医学研究理事会;
关键词
ATP; P2; receptor; purinergic; purinoceptor; renal blood flow; Rouget cell; MEDULLARY BLOOD-FLOW; P2; RECEPTORS; ATP RELEASE; CELLS; CAPILLARIES; RESPONSES; MEMBRANE;
D O I
10.1111/j.1748-1716.2011.02310.x
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Aim: We hypothesized that extracellular nucleotides, established as being released from renal tubular epithelial cells, act at pericytes to regulate vasa recta capillary diameter. Methods: A rat live kidney slice model and video imaging techniques were used to investigate the effects of extracellular nucleotides on in situ (subsurface) vasa recta diameter at pericyte and non-pericyte sites. In addition, RT-qPCR was used to quantify P2 receptor mRNA expression in isolated vasa recta. Results: Extracellular ATP, UTP, benzylbenzyl ATP (BzATP) or 2-methyl-thioATP (2meSATP) evoked a significantly greater vasoconstriction of subsurface vasa recta at pericytes than at non-pericyte sites. The rank order of agonist potency was BzATP = 2meSATP > ATP = UTP. The vasoconstriction evoked at pericyte sites by ATP was significantly attenuated by the P2 receptor antagonists suramin, pyridoxal phosphate-6-azo(benzene-2,4-di-sulfonic acid) (PPADS) or Reactive Blue-2 (RB-2). UTP-evoked vasoconstriction at pericytes was attenuated by suramin or RB-2 but not PPADS. Interestingly, suramin or PPADS, when applied in the absence of a P2 receptor agonist, evoked a weak but significant vasoconstriction of vasa recta at pericyte sites, suggesting tonic vasodilation by nucleotides. Significant levels of P2X(1, 3 and 7) and P2Y(4 and 6) receptor mRNA were detected in vasa recta. Conclusion: Extracellular nucleotides act at pericytes to cause vasoconstriction of in situ vasa recta. Pharmacological characterization, supported by RT-qPCR data, suggests that P2X(1 and 7) and P2Y(4) receptors mediate nucleotide-evoked vasoconstriction of vasa recta by pericytes. We propose that nucleotides released from renal tubular epithelial cells, in close proximity to vasa recta capillaries, are key in regulating renal medullary blood flow.
引用
收藏
页码:241 / 251
页数:11
相关论文
共 37 条
[31]   THE PERICYTE - A REVIEW [J].
SIMS, DE .
TISSUE & CELL, 1986, 18 (02) :153-174
[32]   ATP: The red blood cell link to NO and local control of the pulmonary circulation [J].
Sprague, RS ;
Ellsworth, ML ;
Stephenson, AH ;
Lonigro, AJ .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1996, 271 (06) :H2717-H2722
[33]   PERICYTE-ENDOTHELIAL RELATIONSHIPS IN CARDIAC AND SKELETAL-MUSCLE CAPILLARIES [J].
TILTON, RG ;
KILO, C ;
WILLIAMSON, JR .
MICROVASCULAR RESEARCH, 1979, 18 (03) :325-335
[34]   Adenosine 5′-triphosphate:: a P2-Purinergic agonist in the myocardium [J].
Vassort, G .
PHYSIOLOGICAL REVIEWS, 2001, 81 (02) :767-806
[35]   Sodium-dependent regulation of renal amiloride-sensitive currents by apical P2 receptors [J].
Wildman, Scott S. P. ;
Marks, Joanne ;
Turner, Clare M. ;
Yew-Booth, Liang ;
Peppiatt-Wildman, Claire M. ;
King, Brian F. ;
Shirley, David G. ;
Wang, WenHui ;
Unwin, Robert J. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 19 (04) :731-742
[36]   P2X receptors: Epithelial ion channels and regulators of salt and water transport [J].
Wildman, Scott S. P. ;
King, Brian F. .
NEPHRON PHYSIOLOGY, 2008, 108 (03) :60-67
[37]   Sensitization by extracellular Ca2+ of rat P2X5 receptor and its pharmacological properties compared with rat P2X1• [J].
Wildman, SS ;
Brown, SG ;
Rahman, M ;
Noel, CA ;
Churchill, L ;
Burnstock, G ;
Unwin, RJ ;
King, BF .
MOLECULAR PHARMACOLOGY, 2002, 62 (04) :957-966